Eli Lilly and Co (LLY) reported last week that its anti-diabetic drug Peglispro showed better results in its Phase-III trials compared to the already approved Sanofi (SNY) Lantus.
This once-daily insulin treatment is capable of reducing blood sugar levels in type 1 and 2 diabetic patients. Lilly plans to file the New Drug Approval (NDA) for Peglispro by early 2015 in US and Europe.
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes. The battle started with the launch of Sanofi’s Lantus (insulin glargine) and Novo’s Levemir. Both drugs fall under the category of long-acting basal insulin used for controlling the blood glucose levels in diabetic patients.
Eli Lilly and Co (LLY) announced on Monday, that the US Food and Drug Administration (FDA) had given tentative approval to its diabetes insulin drug called Basaglar. The development of this drug, which is administered intraveneously and aims to control blood sugar levels in diabetic patients, is a joint effort by Eli Lilly and Boehringer Ingelheim Corporation.
Novo Nordisk A/S (ADR) (NVO) announced yesterday, that its insulin therapy Tresiba, which was in late-stage trials, has proved to be safe and effective for the treatment of type 1 diabetes in children and young adults.
Data from the trials was presented at the European Association for the Study of Diabetes (EASD) held in Vienna from September 16-19.
Eli Lilly & Co announced yesterday it is ready to launch Abasria, a cheaper biosimilar version of Sanofi's blockbuster diabetic drug, Lantus. The company will release Abasria in Europe when the European patents for the original drug expire in May. Following the news, Sanofi stock dropped more than 3%.
Biosimilars are a cheaper version of original biologic drugs, and are similar to the original drugs but not their exact copy. Several biosimilar drugs have been approved in Europe since 2008, whereas the US FDA is still to approve the first biosimilar for the US market.
Eli Lilly and Co (NYSE:LLY) announced yesterday that its type 2 diabetes treatment for adults, Trulicity, has been granted marketing approval by the European Commission. The drug has already received the US Food and Drug Administration’s (FDA) approval in September for the treatment of type 2 diabetes in adults.
Sanofi SA (ADR) (NYSE:SNY) announced after markets closed for trading on Wednesday that it has received marketing approval from the US Food and Drug Administration (FDA) to sell its new insulin product Toujeo in the US market. The approval is crucial for the French-based company as it attempts to maintain its leadership in the lucrative diabetes market, at a time when its star drug Lantus is set to lose patent protection soon.